ResMed Posts 46% EPS Beat with $2.81 Q2 Fiscal 2026 Results
ResMed Inc. delivered fiscal 2026 second-quarter adjusted EPS of $2.81, surpassing consensus by 46% and beating estimates in three of the trailing four quarters. Quarterly revenues reached $1.42 billion, topping forecasts by 2.3%, while earnings yield of 7.1% outpaced the 2.8% industry average.
1. Second-Quarter Fiscal 2026 EPS Surges 46%
ResMed reported adjusted EPS of $2.81 for its fiscal second quarter, representing a 46% increase over consensus estimates. This performance marks three beats in the last four quarters, with an average surprise of 2.7%.
2. Revenues Top Estimates at $1.42 Billion
Quarterly revenues reached $1.42 billion, exceeding analyst forecasts by 2.3%, driven by robust demand in key respiratory care markets. The top-line growth underscores continued strength in the company’s core patient-monitoring devices.
3. Strong Earnings Yield Versus Industry Peers
The company posted an earnings yield of 7.1%, outpacing the industry average of 2.8%. This yield differential highlights ResMed’s attractive profitability profile compared to equipment and device peers.
4. Consistent Earnings Surprises Over Trailing Quarters
ResMed has delivered three positive earnings surprises and one miss over the past four quarters, reflecting stable execution and effective cost management despite market headwinds.